Ultragenyx prices $300M public offering of common stock and pre-funded warrants

On October 18, 2023, Ultragenyx Pharmaceutical Inc. (“ Ultragenyx ” or the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, BofA Securities, Inc., and Cowen and Company, LLC (the “ Underwriters ”), providing for the offer and sale in an underwritten public offering (the “ Offering ”) of 8,333,334 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), and in lieu of Common Stock to certain investors, pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase 1,666,722 shares of Common Stock (the “ Warrant Shares ”).